Item(by='tgb', descendants=None, kids=None, score=None, time=1606935775, title=None, item_type='comment', url=None, parent=25278818, text='I don&#x27;t think that gives an accurate picture of what happened. Even AstraZeneca themselves are calling the half-dosage a mistake. Their US trial of that vaccine does not currently contain a half-dose arm [1], though it likely will be amended to do so. As best I can read it, the dosage amount was planned but it was intended to represent the &quot;full&quot; dosage and not to be a half-dosage, but was updated when they noticed unusually mild physical symptoms in people receiving the vaccine. [2] I haven&#x27;t seen anything to support the idea that a half-dosage was an intended endpoint, whether secondary or otherwise. Do you have a source for that?<p>[1] <a href="https:&#x2F;&#x2F;clinicaltrials.gov&#x2F;ct2&#x2F;show&#x2F;NCT04516746" rel="nofollow">https:&#x2F;&#x2F;clinicaltrials.gov&#x2F;ct2&#x2F;show&#x2F;NCT04516746</a>\n[2] <a href="https:&#x2F;&#x2F;www.reuters.com&#x2F;article&#x2F;uk-health-coronavirus-astrazeneca-oxford&#x2F;decades-of-work-and-half-a-dose-of-fortune-drove-oxford-vaccine-success-idUKKBN2832NG" rel="nofollow">https:&#x2F;&#x2F;www.reuters.com&#x2F;article&#x2F;uk-health-coronavirus-astraz...</a>')